← Eichor
Study identifier: NCT07715136 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

Condition: Inflammatory Myopathy  ·  Sponsor: iCell Gene Therapeutics

PhasePhase 1
Planned participants10
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).

This description comes directly from the study's public registry record.

Talk to the study team

Qibing Xie  ·  +86-28-85422391  ·  xieqibing1971@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China Hospital, Sichuan UniversityChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07715136